The following 9 SCLC clinical trials are available to participate in the UK:
Study Evaluating Safety, Tolerability and PK of AMG 757 in Adults With Small Cell Lung Cancer (Phase 1, enrolling 382 patients; Interventional)
A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype. (Phase 1|Phase 2, enrolling 135 patients; Interventional)
A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors (Phase 2, enrolling 264 patients; Interventional)
Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411 (Phase 1|Phase 2, enrolling 60 patients; Interventional)
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors (Phase 1, enrolling 100 patients; Interventional)
eRAPID: Online Symptom Reporting in Lung Cancer (Not Applicable, enrolling 100 patients; Interventional)
Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013) (Phase 3, enrolling 672 patients; Interventional)
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (Phase 1|Phase 2, enrolling 715 patients; Interventional)
A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer (Phase 3, enrolling 690 patients; Interventional)